拘束性ペプチド薬の世界市場レポート 2025年

拘束性ペプチド薬の市場規模は今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は17.0％で、61億3,000万米ドルに成長します。予測期間の成長は、標的治療や個別化治療に対する需要の高まり、拘束ペプチドの結合親和性や細胞への取り込みの改善、ペプチド研究に対する政府・民間投資の増加、合成拘束技術の進歩、腫瘍学や代謝性疾患における応用範囲の拡大などに起因すると考えられます。予測期間中に予想される主要動向には、固相とマイクロ波支援ペプチド合成の進展、ペプチドのステープリング法と大環状化法の開発、ペプチド設計における人工知能と機械学習の統合、サステイナブルペプチド生産のためのグリーンケミストリーの採用、ペプチド-タンパク質コンジュゲートと細胞透過性ペプチドの使用が含まれます。

標的治療に対する需要の高まりが、今後数年間の拘束性ペプチド薬市場の成長を牽引すると予想されます。標的治療とは、疾患の開発や進行に関与する分子経路と特異的に相互作用するように設計された治療です。この需要の高まりは、従来型治療に比べて精度が高く、副作用が少ないことに起因しています。標的治療は、特定の分子メカニズムに特化することで、治療の精度を高め、拘束性ペプチド薬の開発をサポートします。副作用を最小限に抑えながら薬効を高めるため、拘束ペプチドは複雑な疾患の治療における標的アプローチの有力な候補となります。例えば、2024年12月、米国を拠点とする非営利の医療・科学団体である米国遺伝子細胞治療学会（ASGCT）は、食品医薬品局（FDA）が2023年に6つの遺伝子治療製品を承認し、2022年の5つから増加したと報告しました。したがって、標的療法に対する需要の高まりが拘束性ペプチド薬市場の拡大に拍車をかけています。

拘束性ペプチド薬市場の主要企業は、バイオアベイラビリティを高め、患者のコンプライアンスを向上させ、これまで治療不可能であった病態に対処するために、経口大環状ペプチドのような先進的ドラッグデリバリーソリューションの開発に注力しています。経口大環状ペプチドは、注射とは対照的に、経口投与した場合に安定性を保ち、効果的に吸収されるように特別に設計された環状ペプチドベースの薬剤です。例えば、2024年2月、米国のバイオテクノロジー企業Insamoが経口環状ペプチドを発表しました。このペプチドは膜透過性があり経口投与が可能で、生物製剤の高い特異性と経口投与の利便性を兼ね備えています。インサモのプラットフォームは、機械学習による分子設計、超高スループット分子生物学、並列合成化学を採用し、困難な薬剤標的であっても、望ましい薬理学的特性を持つ前臨床候補化合物を迅速に同定します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の拘束性ペプチド薬：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の拘束性ペプチド薬市場：成長率分析
• 世界の拘束性ペプチド薬市場の実績：規模と成長、2019～2024年
• 世界の拘束性ペプチド薬市場の予測：規模と成長、2024～2029年、2034年
• 世界の拘束性ペプチド薬：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の拘束性ペプチド薬市場：薬剤タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 直鎖ペプチド
• 環状ペプチド
• ステープルペプチド
• 多価ペプチド
• 世界の拘束性ペプチド薬市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 注射剤
• 鼻腔内
• 経皮
• 経口
• 世界の拘束性ペプチド薬市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 生物学ラボ
• その他
• 世界の拘束性ペプチド薬市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 直接販売
• サードパーティディストリビューター
• オンライン薬局
• 小売薬局
• 世界の拘束性ペプチド薬市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 製薬会社
• ラボ
• 専門クリニック
• 世界の拘束性ペプチド薬市場、直鎖ペプチドのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 抗菌ペプチド
• ホルモンペプチド
• 酵素阻害剤
• 受容体作動薬
• 世界の拘束性ペプチド薬市場、環状ペプチドのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 天然環状ペプチド
• 合成環状ペプチド
• ジスルフィド架橋ペプチド
• 頭尾環状ペプチド
• 世界の拘束性ペプチド薬市場、ステープルペプチドのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• アルファヘリックス安定化ペプチド
• 炭化水素連結ペプチド
• 二重ステープルペプチド
• バックボーンステープルペプチド
• 世界の拘束性ペプチド薬市場、多価ペプチドのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 二価ペプチド
• 三価ペプチド
• 四価ペプチド
• ペプチド薬剤複合体

第7章 地域別・国別分析

• 世界の拘束性ペプチド薬市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の拘束性ペプチド薬市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 拘束性ペプチド薬市場：競合情勢
• 拘束性ペプチド薬市場：企業プロファイル
  • AstraZeneca PLC
  • Novartis AG
  • Union Chimique Belge S.A.（UCB）
  • CPC Scientific Inc.
  • PeptiDream Inc.

第31章 その他の大手企業と革新的企業

• Protagonist Therapeutics Inc.
• Bicycle Therapeutics plc
• Zealand Pharma A/S
• Bio-Synthesis Inc.
• Encycle Therapeutics Inc.
• Circle Pharma Inc.
• Issar Pharmaceuticals Inc.
• Aileron Therapeutics Inc.
• Creative Peptides
• Fierce BIoTech
• Lisata Therapeutics Inc.
• Pepscan Therapeutics B.V.
• Phylogica Ltd.
• Pepticom Ltd
• Spexis AG

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 拘束性ペプチド薬市場、2029年：新たな機会を提供する国
• 拘束性ペプチド薬市場、2029年：新たな機会を提供するセグメント
• 拘束性ペプチド薬市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Constrained peptide drugs are peptides that have been chemically modified to maintain a fixed, stable three-dimensional shape, often achieved through cyclization or the introduction of chemical bridges. This structural constraint enhances their stability, improves binding affinity, and increases specificity for target proteins. The primary goal of constrained peptide drugs is to boost therapeutic effectiveness by making them more resistant to degradation and improving their selectivity compared to linear peptides.

The main types of constrained peptide drugs include linear peptides, cyclic peptides, stapled peptides, and multivalent peptides. Linear peptides consist of amino acid chains arranged in a straight, unbranched sequence without any cyclic or cross-linked structures. These drugs can be administered via various routes such as injectable, intranasal, transdermal, and oral methods. Their applications span across hospitals, biological research institutes, and other healthcare settings. Distribution channels include direct sales, third-party distributors, online pharmacies, and retail pharmacies. The end users of these drugs primarily include hospitals, pharmaceutical companies, research laboratories, and specialty clinics.

The constrained peptide drugs market research report is one of a series of new reports from The Business Research Company that provides constrained peptide drugs market statistics, including constrained peptide drugs industry global market size, regional shares, competitors with a constrained peptide drugs market share, constrained peptide drugs market segments, market trends and opportunities, and any further data you may need to thrive in the constrained peptide drugs industry. This constrained peptide drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The constrained peptide drugs market size has grown rapidly in recent years. It will grow from $2.79 billion in 2024 to $3.27 billion in 2025 at a compound annual growth rate (CAGR) of 17.3%. The growth during the historic period can be credited to the rising prevalence of chronic diseases, growing demand for targeted therapies, advancements in drug delivery systems, improved peptide stability through chemical modifications, and regulatory backing for innovative therapeutics.

The constrained peptide drugs market size is expected to see rapid growth in the next few years. It will grow to $6.13 billion in 2029 at a compound annual growth rate (CAGR) of 17.0%. The growth in the forecast period can be attributed to the rising demand for targeted and personalized therapies, improved binding affinity and cellular uptake of constrained peptides, increasing government and private investments in peptide research, advancements in synthetic constraining techniques, and the widening scope of applications in oncology and metabolic disorders. Key trends expected during the forecast period include progress in solid-phase and microwave-assisted peptide synthesis, the development of peptide stapling and macrocyclization methods, the integration of artificial intelligence and machine learning in peptide design, the adoption of green chemistry for sustainable peptide production, and the use of peptide-protein conjugates and cell-penetrating peptides.

The rising demand for targeted therapies is anticipated to drive the growth of the constrained peptide drugs market in the coming years. Targeted therapies are medical treatments designed to specifically interact with molecular pathways responsible for the development and progression of diseases. This growing demand stems from their greater precision and fewer side effects compared to traditional treatments. Targeted therapies support the development of constrained peptide drugs by honing in on specific molecular mechanisms, thereby enhancing treatment accuracy. They increase drug effectiveness while minimizing adverse effects, positioning constrained peptides as strong candidates for targeted approaches in treating complex diseases. For example, in December 2024, the American Society of Gene & Cell Therapy (ASGCT), a U.S.-based non-profit medical and scientific organization, reported that the Food and Drug Administration (FDA) approved six gene therapy products in 2023, an increase from five in 2022. Hence, the growing demand for targeted therapies is fueling the expansion of the constrained peptide drugs market.

Leading companies in the constrained peptide drugs market are concentrating on developing advanced drug delivery solutions, such as oral macrocyclic peptides, to enhance bioavailability, boost patient compliance, and address previously untreatable conditions. Oral macrocyclic peptides are cyclic peptide-based drugs specifically designed to remain stable and be effectively absorbed when administered orally, as opposed to injections. For example, in February 2024, Insamo, a U.S.-based biotechnology firm, introduced oral cyclic peptides. These peptides are membrane-permeable and orally available, combining the high specificity of biologics with the convenience of oral delivery. Insamo's platform employs machine learning-guided molecular design, ultra-high-throughput molecular biology, and parallel synthetic chemistry to swiftly identify preclinical candidates with desirable pharmacological properties, even for difficult drug targets.

In March 2023, Ono Pharmaceutical Co. Ltd., a pharmaceutical company based in Japan, partnered with PeptiDream Inc. to discover and develop new macrocyclic constrained peptide drugs. This collaboration seeks to utilize PeptiDream's proprietary Peptide Discovery Platform System (PDPS) to create high-affinity macrocyclic peptides aimed at challenging protein-protein interactions for novel drug development. PeptiDream Inc. is a Japan-based biotechnology firm specializing in the discovery and development of constrained peptide drugs.

Major players in the constrained peptide drugs market are AstraZeneca PLC, Novartis AG, Union Chimique Belge S.A. (UCB), CPC Scientific Inc., PeptiDream Inc., Protagonist Therapeutics Inc., Bicycle Therapeutics plc, Zealand Pharma A/S, Bio-Synthesis Inc., Encycle Therapeutics Inc., Circle Pharma Inc., Issar Pharmaceuticals Inc., Aileron Therapeutics Inc., Creative Peptides, Fierce Biotech, Lisata Therapeutics Inc., Pepscan Therapeutics B.V., Phylogica Ltd., Pepticom Ltd, and Spexis AG.

North America was the largest region in the constrained peptide drugs market in 2024. The regions covered in constrained peptide drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the constrained peptide drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The constrained peptide drugs market consists of sales of stapled peptides, modified peptide hormone analogs and cyclotides, and engineered natural peptides. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that businesses gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Constrained Peptide Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on constrained peptide drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for constrained peptide drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The constrained peptide drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Linear Peptides; Cyclic Peptides; Stapled Peptides; Multivalent Peptides
• 2) By Route Of Administration: Injectable; Intranasal; Transdermal; Oral
• 3) By Application: Hospital; Institute Of Biology; Other Applications
• 4) By Distribution Channel: Direct Sales; Third-Party Distributors; Online Pharmacies; Retail Pharmacies
• 5) By End User: Hospitals; Pharmaceutical Companies; Research Laboratories; Specialty Clinics
• Subsegments:
• 1) By Linear Peptides: Antimicrobial Peptides; Hormonal Peptides; Enzyme Inhibitors; Receptor Agonists
• 2) By Cyclic Peptides: Natural Cyclic Peptides; Synthetic Cyclic Peptides; Disulfide-Bridged Peptides; Head-To-Tail Cyclized Peptides
• 3) By Stapled Peptides: Alpha-Helix Stabilized Peptides; Hydrocarbon-Stapled Peptides; Double-Stapled Peptides; Backbone-Stapled Peptides
• 4) By Multivalent Peptides: Bivalent Peptides; Trivalent Peptides; Tetravalent Peptides; Peptide-Drug Conjugates
• Companies Mentioned: AstraZeneca PLC; Novartis AG; Union Chimique Belge S.A. (UCB); CPC Scientific Inc.; PeptiDream Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Constrained Peptide Drugs Market Characteristics

3. Constrained Peptide Drugs Market Trends And Strategies

4. Constrained Peptide Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Constrained Peptide Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Constrained Peptide Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Constrained Peptide Drugs Market Growth Rate Analysis
• 5.4. Global Constrained Peptide Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Constrained Peptide Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Constrained Peptide Drugs Total Addressable Market (TAM)

6. Constrained Peptide Drugs Market Segmentation

• 6.1. Global Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Linear Peptides
• Cyclic Peptides
• Stapled Peptides
• Multivalent Peptides
• 6.2. Global Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable
• Intranasal
• Transdermal
• Oral
• 6.3. Global Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Institute Of Biology
• Other Applications
• 6.4. Global Constrained Peptide Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Direct Sales
• Third-Party Distributors
• Online Pharmacies
• Retail Pharmacies
• 6.5. Global Constrained Peptide Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Pharmaceutical Companies
• Research Laboratories
• Specialty Clinics
• 6.6. Global Constrained Peptide Drugs Market, Sub-Segmentation Of Linear Peptides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antimicrobial Peptides
• Hormonal Peptides
• Enzyme Inhibitors
• Receptor Agonists
• 6.7. Global Constrained Peptide Drugs Market, Sub-Segmentation Of Cyclic Peptides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Natural Cyclic Peptides
• Synthetic Cyclic Peptides
• Disulfide-Bridged Peptides
• Head-To-Tail Cyclized Peptides
• 6.8. Global Constrained Peptide Drugs Market, Sub-Segmentation Of Stapled Peptides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alpha-Helix Stabilized Peptides
• Hydrocarbon-Stapled Peptides
• Double-Stapled Peptides
• Backbone-Stapled Peptides
• 6.9. Global Constrained Peptide Drugs Market, Sub-Segmentation Of Multivalent Peptides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bivalent Peptides
• Trivalent Peptides
• Tetravalent Peptides
• Peptide-Drug Conjugates

7. Constrained Peptide Drugs Market Regional And Country Analysis

• 7.1. Global Constrained Peptide Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Constrained Peptide Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Constrained Peptide Drugs Market

• 8.1. Asia-Pacific Constrained Peptide Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Constrained Peptide Drugs Market

• 9.1. China Constrained Peptide Drugs Market Overview
• 9.2. China Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Constrained Peptide Drugs Market

• 10.1. India Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Constrained Peptide Drugs Market

• 11.1. Japan Constrained Peptide Drugs Market Overview
• 11.2. Japan Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Constrained Peptide Drugs Market

• 12.1. Australia Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Constrained Peptide Drugs Market

• 13.1. Indonesia Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Constrained Peptide Drugs Market

• 14.1. South Korea Constrained Peptide Drugs Market Overview
• 14.2. South Korea Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Constrained Peptide Drugs Market

• 15.1. Western Europe Constrained Peptide Drugs Market Overview
• 15.2. Western Europe Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Constrained Peptide Drugs Market

• 16.1. UK Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Constrained Peptide Drugs Market

• 17.1. Germany Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Constrained Peptide Drugs Market

• 18.1. France Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Constrained Peptide Drugs Market

• 19.1. Italy Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Constrained Peptide Drugs Market

• 20.1. Spain Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Constrained Peptide Drugs Market

• 21.1. Eastern Europe Constrained Peptide Drugs Market Overview
• 21.2. Eastern Europe Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Constrained Peptide Drugs Market

• 22.1. Russia Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Constrained Peptide Drugs Market

• 23.1. North America Constrained Peptide Drugs Market Overview
• 23.2. North America Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Constrained Peptide Drugs Market

• 24.1. USA Constrained Peptide Drugs Market Overview
• 24.2. USA Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Constrained Peptide Drugs Market

• 25.1. Canada Constrained Peptide Drugs Market Overview
• 25.2. Canada Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Constrained Peptide Drugs Market

• 26.1. South America Constrained Peptide Drugs Market Overview
• 26.2. South America Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Constrained Peptide Drugs Market

• 27.1. Brazil Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Constrained Peptide Drugs Market

• 28.1. Middle East Constrained Peptide Drugs Market Overview
• 28.2. Middle East Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Constrained Peptide Drugs Market

• 29.1. Africa Constrained Peptide Drugs Market Overview
• 29.2. Africa Constrained Peptide Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Constrained Peptide Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Constrained Peptide Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Constrained Peptide Drugs Market Competitive Landscape And Company Profiles

• 30.1. Constrained Peptide Drugs Market Competitive Landscape
• 30.2. Constrained Peptide Drugs Market Company Profiles
  • 30.2.1. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Union Chimique Belge S.A. (UCB) Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. CPC Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. PeptiDream Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Constrained Peptide Drugs Market Other Major And Innovative Companies

• 31.1. Protagonist Therapeutics Inc.
• 31.2. Bicycle Therapeutics plc
• 31.3. Zealand Pharma A/S
• 31.4. Bio-Synthesis Inc.
• 31.5. Encycle Therapeutics Inc.
• 31.6. Circle Pharma Inc.
• 31.7. Issar Pharmaceuticals Inc.
• 31.8. Aileron Therapeutics Inc.
• 31.9. Creative Peptides
• 31.10. Fierce Biotech
• 31.11. Lisata Therapeutics Inc.
• 31.12. Pepscan Therapeutics B.V.
• 31.13. Phylogica Ltd.
• 31.14. Pepticom Ltd
• 31.15. Spexis AG

32. Global Constrained Peptide Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Constrained Peptide Drugs Market

34. Recent Developments In The Constrained Peptide Drugs Market

35. Constrained Peptide Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Constrained Peptide Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Constrained Peptide Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Constrained Peptide Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer